Keryx Biopharmaceuticals Company Profile (NASDAQ:KERX)

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals logoKeryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company's product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis. The Company operates through the products segment. Auryxia can bind to phosphate in the gastrointestinal tract and form non-absorbable complexes to reduce intestinal absorption and aid in the management of hyperphosphatemia in patients with CKD. The adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, constipation, vomiting and cough. The Company focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: KERX
  • CUSIP: 49251510
Key Metrics:
  • Previous Close: $4.99
  • 50 Day Moving Average: $5.48
  • 200 Day Moving Average: $5.22
  • 52-Week Range: $3.17 - $7.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.82
  • P/E Growth: -0.03
  • Market Cap: $505.43M
  • Outstanding Shares: 105,960,000
  • Beta: 4.93
  • Net Margins: -584.76%
  • Return on Equity: -270.26%
  • Return on Assets: -67.88%
  • Debt-to-Equity Ratio: 5.69%
  • Current Ratio: 8.75%
  • Quick Ratio: 7.42%
Additional Links:
Companies Related to Keryx Biopharmaceuticals:

Analyst Ratings

Consensus Ratings for Keryx Biopharmaceuticals (NASDAQ:KERX) (?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $8.83 (85.19% upside)

Analysts' Ratings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
DateFirmActionRatingPrice TargetDetails
1/11/2017Citigroup Inc.UpgradeSell -> Neutral$7.00View Rating Details
11/19/2016FBR & CoReiterated RatingHoldView Rating Details
11/9/2016Maxim GroupUpgradeHold -> Buy$7.00View Rating Details
9/8/2016JMP SecuritiesReiterated RatingOutperformView Rating Details
8/3/2016Cowen and CompanyReiterated RatingNeutralView Rating Details
8/2/2016Raymond James Financial, Inc.Boost Price TargetOutperform$7.00 -> $10.00View Rating Details
8/2/2016Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$9.00 -> $10.00View Rating Details
8/2/2016Brean CapitalDowngradeBuy -> HoldView Rating Details
8/2/2016Stifel NicolausDowngradeBuy -> HoldView Rating Details
4/30/2016Morgan StanleyReiterated RatingHoldView Rating Details
3/29/2016BTIG ResearchReiterated RatingSell$2.50View Rating Details
2/26/2016J P Morgan Chase & CoDowngradeOverweight -> NeutralView Rating Details
8/10/2015Roth CapitalDowngradeBuy -> Neutral$11.00 -> $6.00View Rating Details
8/7/2015MLV & Co.Reiterated RatingBuy$25.00View Rating Details
5/6/2015MizuhoLower Price TargetBuy$25.00 -> $21.00View Rating Details
3/20/2015Oppenheimer Holdings, Inc.Lower Price TargetOutperform$22.00 -> $18.00View Rating Details
(Data available from 2/23/2015 forward)


Earnings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017ListenView Earnings Details
11/9/2016Q316($0.20)($0.39)$5.53 million$6.30 millionViewListenView Earnings Details
8/1/2016Q216($0.28)($0.42)$8.60 million$9.30 millionViewListenView Earnings Details
4/28/2016Q116($0.26)($0.39)$6.63 million$6.80 millionViewListenView Earnings Details
2/25/2016Q415($0.25)($0.36)$5.68 million$5.80 millionViewListenView Earnings Details
10/29/2015($0.25)($0.29)$3.91 million$4.21 millionViewListenView Earnings Details
8/5/2015Q215($0.26)($0.26)$2.86 million$2.50 millionViewListenView Earnings Details
5/4/2015Q115($0.30)($0.28)$2.45 million$1.20 millionViewListenView Earnings Details
2/27/2015Q414($0.38)($0.44)$1.39 millionViewListenView Earnings Details
11/6/2014Q314($0.27)($0.38)$0.26 millionViewListenView Earnings Details
8/7/2014Q214($0.25)($0.24)$0.28 millionViewListenView Earnings Details
5/8/2014Q114($0.08)($0.15)$9.91 million$10.00 millionViewListenView Earnings Details
3/12/2014Q413($0.16)($0.21)$2.22 millionViewListenView Earnings Details
11/5/2013Q313($0.11)($0.19)$2.22 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.10)($0.14)ViewListenView Earnings Details
5/7/2013Q1 2013($0.01)($0.03)$5.83 million$7.00 millionViewListenView Earnings Details
3/12/2013Q4 2012($0.08)($0.09)ViewListenView Earnings Details
11/7/2012Q312($0.07)($0.08)ViewN/AView Earnings Details
8/7/2012($0.09)($0.02)ViewN/AView Earnings Details
5/8/2012($0.12)($0.13)ViewN/AView Earnings Details
2/29/2012($0.14)($0.12)ViewN/AView Earnings Details
8/8/2011($0.03)($0.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)
Current Year EPS Consensus Estimate: $-1.45 EPS
Next Year EPS Consensus Estimate: $-0.61 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.23)($0.23)($0.23)
Q2 20161($0.21)($0.21)($0.21)
Q3 20161($0.23)($0.23)($0.23)
Q4 20161($0.31)($0.31)($0.31)
(Data provided by Zacks Investment Research)


Dividend History for Keryx Biopharmaceuticals (NASDAQ:KERX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Insider Ownership Percentage: 3.08%
Institutional Ownership Percentage: 61.74%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/30/2017Brian AdamsGeneral CounselSell6,984$4.65$32,475.60View SEC Filing  
1/30/2017Greg MadisonInsiderSell18,248$4.65$84,853.20View SEC Filing  
1/30/2017Scott A. HolmesCFOSell8,447$4.65$39,278.55View SEC Filing  
1/23/2017John F. NeylanInsiderSell1,428$5.39$7,696.92View SEC Filing  
1/17/2017Brian AdamsVPSell1,265$6.24$7,893.60View SEC Filing  
1/5/2017Brian AdamsVPSell759$6.16$4,675.44View SEC Filing  
1/5/2017Greg MadisonInsiderSell1,077$6.16$6,634.32View SEC Filing  
10/28/2016Scott A. HolmesCFOSell1,237$4.44$5,492.28View SEC Filing  
10/24/2016John F. NeylanInsiderSell1,211$4.72$5,715.92View SEC Filing  
10/17/2016Brian AdamsVPSell1,106$4.86$5,375.16View SEC Filing  
10/5/2016Brian AdamsVPSell647$5.38$3,480.86View SEC Filing  
10/5/2016Greg MadisonInsiderSell917$5.38$4,933.46View SEC Filing  
8/9/2016Greg MadisonInsiderSell1,622$4.22$6,844.84View SEC Filing  
7/29/2016Scott A. HolmesCFOSell4,935$7.36$36,321.60View SEC Filing  
7/25/2016John F. NeylanInsiderSell1,217$7.43$9,042.31View SEC Filing  
7/15/2016Brian AdamsVPSell1,083$7.01$7,591.83View SEC Filing  
7/5/2016Brian AdamsVPSell660$6.66$4,395.60View SEC Filing  
7/5/2016Greg MadisonCEOSell936$6.66$6,233.76View SEC Filing  
5/9/2016Greg MadisonCEOSell1,873$5.42$10,151.66View SEC Filing  
4/25/2016John F NeylanInsiderSell4,766$5.21$24,830.86View SEC Filing  
4/15/2016Brian AdamsVPSell1,060$5.05$5,353.00View SEC Filing  
4/5/2016Brian AdamsVPSell759$4.50$3,415.50View SEC Filing  
4/5/2016Greg MadisonCEOSell1,078$4.50$4,851.00View SEC Filing  
2/9/2016Greg MadisonCEOSell1,938$3.23$6,259.74View SEC Filing  
1/15/2016Brian AdamsVPSell1,322$3.30$4,362.60View SEC Filing  
1/6/2016Brian AdamsVPSell3,004$5.16$15,500.64View SEC Filing  
1/6/2016Greg MadisonCEOSell4,261$4.83$20,580.63View SEC Filing  
11/4/2015Scott A. HolmesCFOBuy5,000$5.33$26,650.00View SEC Filing  
10/15/2015Brian AdamsVPSell1,011$4.01$4,054.11View SEC Filing  
8/21/2015Scott A HolmesCFOBuy5,000$5.72$28,600.00View SEC Filing  
7/15/2015Brian AdamsVPSell1,086$9.99$10,849.14View SEC Filing  
7/6/2015James F Oliviero IIICFOSell1,943$9.61$18,672.23View SEC Filing  
5/6/2015Michael P TarnokDirectorBuy10,000$9.73$97,300.00View SEC Filing  
4/15/2015Brian AdamsVPSell4,320$12.40$53,568.00View SEC Filing  
4/6/2015James F Oliviero IIICFOSell1,878$11.68$21,935.04View SEC Filing  
4/6/2015Ron BentsurCEOSell1,592$11.68$18,594.56View SEC Filing  
3/6/2015Greg MadisonCOOBuy6,380$12.53$79,941.40View SEC Filing  
2/9/2015Greg MadisonCOOSell6,759$10.95$74,011.05View SEC Filing  
1/5/2015James F Oliviero IIICFOSell5,604$13.79$77,279.16View SEC Filing  
1/5/2015Ron BentsurCEOSell5,574$13.79$76,865.46View SEC Filing  
12/30/2014Ron BentsurCEOSell200,000$14.11$2,822,000.00View SEC Filing  
12/29/2014Ron BentsurCEOSell338,977$13.98$4,738,898.46View SEC Filing  
10/6/2014Ron BentsurCEOSell70,838$15.88$1,124,907.44View SEC Filing  
10/3/2014James F Oliviero IIICFOSell2,694$16.14$43,481.16View SEC Filing  
9/12/2014Ron BentsurCEOSell50,000$14.24$712,000.00View SEC Filing  
9/8/2014James F Oliviero IIICFOSell144,237$15.88$2,290,483.56View SEC Filing  
7/7/2014James F Oliviero IIICFOSell2,054$15.75$32,350.50View SEC Filing  
7/7/2014Ron BentsurCEOSell1,788$15.75$28,161.00View SEC Filing  
4/3/2014James Oliviero IIICFOSell2,087$16.46$34,352.02View SEC Filing  
4/3/2014Ron BentsurCEOSell1,816$16.46$29,891.36View SEC Filing  
3/21/2014James Oliviero IIICFOSell292,483$15.14$4,428,192.62View SEC Filing  
1/3/2014James Oliviero IIICFOSell6,309$12.57$79,304.13View SEC Filing  
1/3/2014Ron BentsurCEOSell5,257$12.57$66,080.49View SEC Filing  
12/30/2013James Oliviero IIICFOSell109,500$12.64$1,384,080.00View SEC Filing  
10/3/2013James Oliviero IIICFOSell1,475$10.25$15,118.75View SEC Filing  
10/3/2013Ron BentsurCEOSell2,505$10.25$25,676.25View SEC Filing  
7/5/2013James F Oliviero IIICFOSell1,438$7.95$11,432.10View SEC Filing  
7/5/2013Ron BentsurCEOSell2,440$7.95$19,398.00View SEC Filing  
5/13/2013James F Oliviero IIICFOSell29,363$8.34$244,887.42View SEC Filing  
10/3/2012James F Oliviero IIICFOSell4,973$2.72$13,526.56View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Keryx Biopharmaceuticals (NASDAQ:KERX)
News IconStocks on the Move: Louisiana-Pacific Corp. (NYSE:LPX), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) - The Newburgh Press (NASDAQ:KERX) - February 22 at 12:26 PM
News IconKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Quarterly EPS At ... - Stock Observer (NASDAQ:KERX) - February 22 at 12:26 PM
News IconStock Price of Keryx Biopharmaceuticals, Inc. (KERX) Decreases -7.16% - Highland Mirror (NASDAQ:KERX) - February 22 at 12:26 PM
News IconKeryx Biopharmaceuticals (NASDAQ:KERX): Check on Price Target - Post Registrar (NASDAQ:KERX) - February 20 at 10:25 AM
News IconBrokerage Firm Target Review on Keryx Biopharmaceuticals, Inc ... - Rockville Register (NASDAQ:KERX) - February 19 at 10:11 AM logoKeryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2016 Financial Results … (NASDAQ:KERX) - February 18 at 10:08 AM
News IconTrading Indicator Check on Keryx Biopharmaceuticals Inc. (KERX) - Benton Bulletin (NASDAQ:KERX) - February 17 at 6:03 PM logoKeryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 1, 2017 (NASDAQ:KERX) - February 16 at 5:47 PM
News IconStock Trading Focus for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) - Rives Journal (NASDAQ:KERX) - February 15 at 12:36 AM
News IconKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Quarterly EPS At $-0.1 - Stock Observer (NASDAQ:KERX) - February 15 at 12:36 AM
News IconKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Bearish Target At $9 - Stock Observer (NASDAQ:KERX) - February 14 at 12:16 AM
News IconTale of the Tape: Technical Recap for Keryx Biopharmaceuticals Inc. (KERX) - Baldwin Journal (NASDAQ:KERX) - February 14 at 12:16 AM logoKeryx Biopharmaceuticals to Webcast its Presentation at RBC Capital Markets' 2017 Global Healthcare Conference on ... - GlobeNewswire (press release) (NASDAQ:KERX) - February 10 at 12:08 AM
News IconKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Daily Sentiment Score At 0.343 - Stock Observer (NASDAQ:KERX) - February 10 at 12:08 AM logoKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Is Expected To Post EPS Of $-0.1 - (NASDAQ:KERX) - February 10 at 12:08 AM logoKeryx Biopharmaceuticals to Webcast its Presentation at RBC Capital Markets' 2017 Global Healthcare Conference on February 22, 2017 (NASDAQ:KERX) - February 8 at 6:55 PM
News IconEarnings Analysis: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) - The Oracle Examiner (NASDAQ:KERX) - February 6 at 10:20 AM
News IconStock Price of Keryx Biopharmaceuticals, Inc. (KERX) Increases ... - Morning Outlook (NASDAQ:KERX) - February 6 at 10:20 AM
News IconKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Quarterly EPS Review - The Newburgh Press (NASDAQ:KERX) - February 3 at 6:50 PM
News IconVery Narrowly Mixed Session (NASDAQ:KERX) - February 2 at 11:53 PM logoHere's Why Keryx Biopharmaceuticals Soared as Much as 15.1% Today (NASDAQ:KERX) - February 2 at 6:52 PM logoDrug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on MannKind and Keryx (NASDAQ:KERX) - February 1 at 6:57 PM
News IconWhat’s Propelling Keryx Biopharmaceuticals (KERX) to Decrease? The Stock Formed a Bearish Multiple Bottom Pattern (NASDAQ:KERX) - January 30 at 10:28 AM
News IconAnalysts Take: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Projected Earnings & Price Targets - Aiken Advocate (NASDAQ:KERX) - January 29 at 11:27 PM
News IconInvestor Technical Review for Keryx Biopharmaceuticals Inc. (KERX) - Rives Journal (NASDAQ:KERX) - January 28 at 6:15 PM
News IconEarnings Take Center Stage; Analysts Weighing in on Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) - Aiken Advocate (NASDAQ:KERX) - January 27 at 5:55 AM logoEPS Projection Of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) At $-0.1 - (NASDAQ:KERX) - January 26 at 7:53 PM
News IconEarnings in Full Force, Analysts Take Aim at Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) - Wall Street Beacon (NASDAQ:KERX) - January 26 at 7:53 PM
News IconTurbulence Hits These Shares as Volume Spikes: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) - Wall Street Beacon (NASDAQ:KERX) - January 24 at 6:50 PM logoKeryx Biopharmaceuticals, Inc. – Value Analysis (NASDAQ:KERX) : January 23, 2017 (NASDAQ:KERX) - January 23 at 6:26 PM
News IconKeryx Biopharmaceuticals, Inc. (KERX) Under Analyst Spotlight - UK ... - UK Market News (NASDAQ:KERX) - January 20 at 9:22 PM logoKeryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : January 20, 2017 (NASDAQ:KERX) - January 20 at 4:20 PM
News IconInvestor Arena: Keeping an Eye on Keryx Biopharmaceuticals Inc. (KERX) - Rives Journal (NASDAQ:KERX) - January 18 at 11:41 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) - Wall Street Beacon (NASDAQ:KERX) - January 14 at 11:11 PM
News IconWill The Needle Move For Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:KERX) - January 13 at 4:40 AM logoKeryx Biopharma (KERX) Auryxia Phase 3 Trial Data Published in ... - (NASDAQ:KERX) - January 13 at 4:40 AM
News IconKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Quarterly growth Review - The Newburgh Press (NASDAQ:KERX) - January 13 at 4:40 AM logoCompany Update (NASDAQ:KERX): Keryx Biopharmaceuticals Announces Publication of Auryxia Phase 3 Trial Results in JASN (NASDAQ:KERX) - January 12 at 6:38 PM logo9:54 am Keryx Biopharma announces the publication of results from its pivotal Phase 3 study evaluating ferric citrate for iron deficiency anemia in non-dialysis-dependent chronic kidney disease in the online issue of the Journal of the Amer (NASDAQ:KERX) - January 12 at 6:38 PM logoKeryx Biopharmaceuticals Announces Publication of Auryxia® (ferric citrate) Phase 3 Trial Results for Iron Deficiency Anemia (IDA) in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) in Journal of the American Society of Nephrology (NASDAQ:KERX) - January 12 at 6:38 PM logoKeryx Biopharmaceuticals (KERX) Presents At 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:KERX) - January 11 at 11:47 PM logoKeryx Biopharma upgraded by Citigroup (NASDAQ:KERX) - January 11 at 6:45 PM
News IconKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Quarterly EPS Set At $-0.12 - Stock Observer (NASDAQ:KERX) - January 11 at 6:12 AM logoKeryx Biopharma +5.4% on strong preliminary numbers - Seeking Alpha (NASDAQ:KERX) - January 11 at 6:12 AM
News IconArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has Current Market Capitalizaion of $118.7 Million (NASDAQ:KERX) - January 10 at 6:59 PM logo4:14 am Keryx Biopharma provides business update; sees Q4 revs above consensus (NASDAQ:KERX) - January 9 at 6:51 PM logoKERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors o (NASDAQ:KERX) - January 9 at 6:51 PM logoKeryx Biopharmaceuticals Announces Recent Business Progress and Reviews Corporate Strategy at 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:KERX) - January 8 at 10:54 PM logoInsider Trading Activity Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) – insider Sold 1077 shares of Stock - Market Exclusive (NASDAQ:KERX) - January 8 at 5:53 PM
News IconValue Score in View for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) - Wall Street Beacon (NASDAQ:KERX) - January 8 at 5:53 PM


What is Keryx Biopharmaceuticals' stock symbol?

Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."

Where is Keryx Biopharmaceuticals' stock going? Where will Keryx Biopharmaceuticals' stock price be in 2017?

12 brokerages have issued 1 year target prices for Keryx Biopharmaceuticals' shares. Their predictions range from $2.50 to $16.00. On average, they anticipate Keryx Biopharmaceuticals' stock price to reach $8.83 in the next twelve months.

When will Keryx Biopharmaceuticals announce their earnings?

Keryx Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

What are analysts saying about Keryx Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Keryx Biopharmaceuticals stock:

  • According to Zacks Investment Research, "Keryx’s top line is driven by sales of its lead product, Auryxia. We are encouraged by the company’s label expansion efforts on Auryxia in the iron-deficiency anemia (IDA) indication. Moreover, the IDA market holds great potential. However, the company took a hit due to an imminent interruption in the supply of Auryxia in August, because of issues related to the conversion of the active pharmaceutical ingredient (API) into the finished product by its contract manufacturer. Consequently, the company withdrew its guidance for 2016. The supply issue is not expected to be resolved any time soon and will lead to a significant decline in sales. Moreover, it will continue to hurt on Keryx’s shares until supply normalizes. Given that the company is heavily dependent on Auryxia for growth, this development is concerning. Loss estimate have been rising ahead of the company’s Q3 earnings release." (11/1/2016)

  • JMP Securities analysts commented, "Hogan Reward"The expert cited Keryx Biopharmaceuticals (NASDAQ: KERX)'s sulodexide as an example of a development-stage asset that failed such a confirmation in another kidney disease called diabetic nephropathy.The DUET study has rolled over onto the open-label portion, although the active control irbesartan will not be carried forward, thus it may be difficult to detect a treatment benefit."We believe that we will need to wait until year end to determine if the company can convince the FDA that an accelerated approval pathway can meet the agency's needs," analyst Liisa Bayko wrote in a note."Our sensitivity analysis shows that the stock currently reflects the sentiment that accelerated approval is unlikely," (9/8/2016)

  • Maxim Group analysts commented, "We make modest adjustments to our model, but our DCF-derived target price remains €48." (8/1/2016)

  • FBR & Co analysts commented, "We are previewing Keryx’s 2Q16 financial results, following an update with management and analysis of IMS script data for Keryx’s approved drug, Auryxia (ferric citrate). KERX shares are up approximately 85% since our upgrade on February 29, 2016, versus a gain of ~12% for the S&P 500 Index, which reflects our thesis and KERX’s continued execution. In 2Q16, IMS scripts grew ~37% to 7,164 scripts, compared with 1Q16 script growth of ~16% to 5,217 scripts. Assuming a capture rate of 57%, we think total script growth could reach 12,565 for the quarter. We had an opportunity to speak with management and discuss the company’s corporate progress and provide the following takeaways: (1) we believe the 2Q16 IMS script growth highlights continued execution with the Auryxia launch; (2) we see a potential tailwind for Auryxia sales from a price increase in 2H16; and (3) long term, we believe the expansion of Auryxia’s use in non-dialysis Iron Deficiency Anemia (IDA) patients has significant potential to increase prescribing physician awareness and expand the market opportunity for the drug." (7/25/2016)

Who owns Keryx Biopharmaceuticals stock?

Keryx Biopharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Abrams Capital Management L.P. (5.40%), State Street Corp (2.73%), FMR LLC (2.33%), Deerfield Management Co. (1.22%), Royce & Associates LP (0.24%) and Iridian Asset Management LLC CT (0.22%). Company insiders that own Keryx Biopharmaceuticals stock include Brian Adams, Greg Madison, James F Oliviero III, John F Neylan, Michael P Tarnok, Ron Bentsur and Scott A Holmes.

Who sold Keryx Biopharmaceuticals stock? Who is selling Keryx Biopharmaceuticals stock?

Keryx Biopharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, State Street Corp, Royce & Associates LP and Frontier Wealth Management LLC. Company insiders that have sold Keryx Biopharmaceuticals stock in the last year include Brian Adams, Greg Madison, John F Neylan and Scott A Holmes.

Who bought Keryx Biopharmaceuticals stock? Who is buying Keryx Biopharmaceuticals stock?

Keryx Biopharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Deerfield Management Co., Iridian Asset Management LLC CT, Old West Investment Management LLC, Advantage Investment Management LLC, Clough Capital Partners L P and Metropolitan Life Insurance Co. NY. Company insiders that have bought Keryx Biopharmaceuticals stock in the last two years include Greg Madison, Michael P Tarnok and Scott A Holmes.

How do I buy Keryx Biopharmaceuticals stock?

Shares of Keryx Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Keryx Biopharmaceuticals stock cost?

One share of Keryx Biopharmaceuticals stock can currently be purchased for approximately $4.77.

Keryx Biopharmaceuticals (NASDAQ:KERX) Chart for Thursday, February, 23, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Earnings History Chart

Earnings by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Dividend History Chart

Dividend Payments by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Last Updated on 2/23/2017 by Staff